Savara (SVRA) Asset Writedowns and Impairment (2012 - 2018)

Savara (SVRA) reported Asset Writedowns and Impairment of $21.7 million for Q1 2018, up 21037.15% quarter-over-quarter from $102625.0 in Q4 2012.

Savara (SVRA) Asset Writedowns and Impairment (2012 - 2018) Analysis & Trends

Savara (SVRA) has 2 years of Asset Writedowns and Impairment data on file, last reported at $21.7 million in Q1 2018.

Asset Writedowns and Impairment for Q1 2018 came in at $21.7 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $21.7 million (changed N/A YoY), and the FY2018 annual result was $21.7 million, changed N/A from the prior year.
Asset Writedowns and Impairment climbed to $21.7 million in Q1 2018 per SVRA's latest filing, from $102625.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $21.7 million in Q1 2018 and troughed at $21.7 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Savara	1.39 Bn	1.39 Bn	-

Download Data